New York-based Paradigm has raised a significant amount to simplify clinical trials. Its goal is ambitious, but its challenges are many, researchers say.
Previous Story
Sundance, Once a Hotbed for Film Deals, Tries to Find Its Footing
Next Story
Anthropic Said to Be Closing In on $300 Million in New A.I. Funding
